Adding Atezolizumab to mFOLFOX6 Improves DFS Among Patients with Stage III dMMR Colon Cancer By Ogkologos - March 31, 2026 204 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATOMIC study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR ESMO Welcomes European Parliament (EP) report on Psychosocial Risks (PSR) at... September 3, 2026 Dual Inhibition of LAG-3 and PD-1 in Patients with Previously Untreated... January 10, 2022 Study Suggests Some Arthritis Drugs May Actually Stop the Spread of... November 26, 2019 Worse Survival Observed Among Patients Diagnosed with Cancer During the First... February 16, 2026 Load more HOT NEWS How to Cope With Waiting Periods During Cancer: An Expert Perspective Stiff “Hot Spots” Within Tumors Help Doctors Predict Spread of Breast... Exceptional Response to Single-Agent Anti-PD1 Therapy Observed in Patients with Advanced... Understanding Genomic Correlates of Response and Acquired Resistance to FGFR Inhibitors
